Related Experiment Video
Updated: Oct 13, 2026
Processing of Primary Brain Tumor Tissue for Stem Cell Assays and Flow Sorting
Published on: September 25, 2012
Brain Tumor Study Group: a survey of current activities
Abstract:
Improvement in the treatment of patients harboring malignant glioma will probably be seen as small incremental changes as new modalities of treatment are proposed, tested, and substantiated. Uncontrolled phase II studies may provide hints of efficacy. However, the results must be substantiated in carefully controlled phase III evaluations. The Brain Tumor Study Group of the National Cancer Institute has demonstrated that mithramycin is not effective in the treatment of malignant glioma and the overall median survivorship experience is no different than the 23 weeks found in historic controls. Radiotherapy can bring about a meaningful increase in survival as can 1,3-bis(2-chloroethyl)-1-nitrosourea. The combination appears to produce more long-term survivors than either treatment above. Methyl-1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea does not appear to be additive to radiotherapy but is more effective than no therapy at all. Studies of the oncolytic effect of corticosteroids in contradistinction to their cerebral edema controlling effects are being done and will provide meaningful data on this important symptomatolytic therapy.
Insights
Malignant glioma treatment shows incremental progress. Radiotherapy and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) improve survival, with combination therapy yielding more long-term survivors than either alone.
Area of Science:
- Neuro-oncology
- Clinical Cancer Research
Background:
- Malignant glioma treatment advances rely on incremental changes.
- Phase II studies suggest potential therapies, but require Phase III validation.
Purpose of the Study:
- Evaluate the efficacy of various treatments for malignant glioma.
- Determine survival benefits of radiotherapy, BCNU, and other agents.
Main Methods:
- Review of National Cancer Institute Brain Tumor Study Group findings.
- Analysis of data from controlled phase III evaluations.
Main Results:
- Mithramycin showed no efficacy in malignant glioma treatment.
- Radiotherapy and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) significantly increased survival.
- Combination of radiotherapy and BCNU resulted in more long-term survivors.
- Methyl-1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea showed benefit over no therapy but not additive to radiotherapy.
- Ongoing studies investigate corticosteroid oncolytic effects.
Conclusions:
- Radiotherapy and BCNU are effective treatments for malignant glioma.
- Combined radiotherapy and BCNU offer superior survival outcomes.
- Further research into corticosteroids may yield new therapeutic insights.
